For instance, WEE1 expression was increased after EGFR-TKI resistance in NSCLC and the combination of chemotherapy with WEE1 inhibitor might improve the clinical outcome of NSCLC patients with acquired EGFR-TKI resistance (96). This evidence concerns the gene WEE1 and non-small cell lung carcinoma.